

# STERIFINE 5 mg (Finas teride) provides:

- Reduction in Prostate Volume
- Increase in Maximal Urinary Flow Rate
- Risk Reduction of AUR by 57%
- Risk Reduction of Surgery by 55%
- Better Overall Reduction of BPH when combining Sterifine 5 mg to an alpha blocker.
- Reduction of Prostate Cancer by 24.8% 3

#### References

1-McConnell J, Bruskewitz R. The Effect of Finasteride on the Risk of Acute Urinary Retention and the need For Surgical Treatment among men with Prostatic Hyperplasia. N Engl J Med 1998 Feb 338(9):557-563 2-McConnell J, Roehrborn C. The Long Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia. N Engl J Med 2003 Dec 349(25):2387-2398 3-Thompson I, Goodman P. The Influence of Finasteride on the Development of Prostate Cancer. N Engl J Med 2003 July 349(3):215-224

Before prescribing please consult physicians' circular.

\* Registered trade name

#### STERIFINE® Benta manufactured by (BPi)

- State of the art manufacturing facility
- Certified European GMP
- ISO Certified



# WHEN DROSTATE VO

# Sterifine<sup>®</sup>5 Finasteride


PROSTATE VOLUME
BECOMES
A BARRIER







## Sterifine<sup>®</sup>5 Finasteride


## Sterifine<sup>®</sup> 5 Finasteride





Finasteride reduces the Prostate Volume during the first year with sustainable effect thereafter.






Finasteride clearly increases Maximal Urinary Flow Rate within the first 4 Months.

STERIFINE reduces the risk of AUR by 57%.
STERIFINE reduces the risk of Surgery by 55%.

### Combination offers Better Overall Results on BPH

Combination Therapy with STERIFINE and doxazosin (an alpha blocker) significantly reduced the risk of overall clinical BPH than did either drug alone.

STERIFINE 5 mg reduces Prostate Cancer.



Seven Years of Finasteride 5 mg treatment resulted in a 24.8% reduction in the prevalence of Prostate Cancer.